What is Biosystems International?
Biosystems International is an in-vitro diagnostics R&D company dedicated to the early detection of cancer, with a particular focus on lung cancer. Leveraging innovative protein epitope profiling technology, the company has developed Pulmolisa, a groundbreaking blood test designed for the differential diagnosis and early identification of lung cancer. This diagnostic tool holds the potential to dramatically improve patient survival rates by enabling timely health solutions. Biosystems International's strategy involves creating disease-specific plasma protein epitope panels compatible with established protein array and ELISA platforms, targeting healthcare providers and blood collection centers, especially those serving high-risk populations for lung cancer.
How much funding has Biosystems International raised?
Biosystems International has raised a total of $8.5M across 2 funding rounds:
Angel/Seed
$3.9M
Unspecified
$4.6M
Angel/Seed (2005): $3.9M with participation from Societe Generale
Unspecified (2008): $4.6M, investors not publicly disclosed
Key Investors in Biosystems International
Societe Generale
Société Générale is a French multinational financial services company, indicating a potential interest in supporting companies with significant market potential and innovative technologies.
What's next for Biosystems International?
The recent major strategic investment in Biosystems International signals a pivotal moment for the company, likely enabling an acceleration of its R&D efforts and the scaling of its diagnostic solutions. This capital infusion is expected to facilitate the expansion of its market reach, potentially through strategic partnerships and broader clinical adoption of its Pulmolisa test. The company's focus on early detection of lung cancer positions it within a critical and growing segment of the healthcare industry, suggesting a trajectory towards becoming a key player in diagnostic innovation.
See full Biosystems International company page
